

COPY OF PAPERS  
ORIGINALLY FILED

1600 0500 0348 1164



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No: 09/848,967  
Filing Date: May 4, 2001  
Title: *IMMUNOGENIC PEPTIDES AND  
USES THEREOF*  
Inventors: *Calenoff & Ditlow*  
Attorney Docket: 21417-92378  
Group No: not assigned  
Examiner: not assigned

CERTIFICATE OF MAILING

I hereby certify that this correspondence is  
being deposited with the United States  
Postal Service via First Class Mail addressed  
to the Assistant Commissioner for Patents,  
Washington, D.C. 20231

*Alice O. Martin*  
Alice O. Martin

Dated: March 4, 2002

INFORMATION DISCLOSURE STATEMENT

RECEIVED  
APR 04 2002  
TECH CENTER 1600/2900

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

This Information Disclosure Statement constitutes a bona fide attempt to comply with 37 C.F.R. §1.97(b) and §1.98. A copy of each reference cited herein is not provided pursuant to §1.98(d)(1) and (2) as they were furnished for an earlier application, U.S. Ser. No. 09/837,630 filed on April 18, 2001 which is pending and is relied on for an earlier effective filing date under 35 U.S.C. 120. The Information Disclosure Statement submitted in this earlier application does comply with §1.98(a) through (c). Pursuant to 37 C.F.R. § 1.56, this Statement is filed in the application identified above.

No representation is intended that a complete search has been made of the prior art. The filing of this Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in § 1.56(b).

PATENTS

<u>Patent Number</u>	<u>Issue Date</u>	<u>Inventor</u>
5,194,254	Mar. 16, 1993	Barber, <i>et al.</i>
5,593,972	Jan. 14, 1997	Weiner <i>et al.</i>
5,750,110	May 12, 1998	Prieels, <i>et al.</i>
5,817,637	Oct. 6, 1998	Weiner <i>et al.</i>
5,830,876	Nov. 3, 1998	Weiner <i>et al.</i>
5,851,756	Dec. 22, 1998	Steinman <i>et al.</i>
5,871,756	Feb. 16, 1999	Jeffcoat <i>et al.</i>
5,876,735	Mar. 2, 1999	Reed
5,876,966	Mar. 2, 1999	Reed
5,942,235	Aug. 24, 1999	Paoletti
5,981,505	Nov. 9, 1999	Weiner <i>et al.</i>
6,013,268	Jan. 11, 2000	Reed
6,051,237	Apr. 18, 2000	Paterson
6,063,384	May 16, 2000	Morrow, <i>et al.</i>
6,077,663	Jun. 20, 2000	Curiel, <i>et al.</i>

6,080,399

Jun. 27, 2000

Gajewski, *et al.*

6,080,409

Jun. 27, 2000

Laus, *et al.*

OTHER DOCUMENTS

BEN-YEDIDIA, T., *et al.* (1999) "Intranasal Administration of Peptide Vaccine Protects Human/Mouse Radiation Chimera from Influenza Infection." *International Immunology* 11(7): 1043-1051.

CASADEVALL, A. and SCHARFF, M.D. (1995) "Return to the Past: The Case for Antibody-Based Therapies in Infectious Diseases." *Clinical Infectious Diseases* 21: 150-61.

FAUCHERE, Jean-Luc and PLIŠKA, V. (1983) "Hydrophobic Parameters ¶ of Amino-Acid Side of N-Acetyl-Amino-Acid Amides." *Eur. J. Med. Chem. – Chim. Ther.*, 18(4): 369-375.

HARRISON, L.C. (1995) "Antigen-Specific Therapy for Autoimmune Disease: Prospects for the Prevention of Insulin-Dependent Diabetes." *Molecular Medicine*, 1(7): 722-727.

HOPP, T.P. and WOODS, K.R. (1981) "Prediction of Protein Antigenic Determinants from Amino Acid Sequences." *Proc. Natl. Acad. Sci. USA* 78(6): 3824-3828.

HUTCHINGS, P. and COOKE, A. (1998) "Protection from Insulin Dependent Diabetes Mellitus Afforded by Insulin Antigens in Incomplete Freund's Adjuvant Depends on Route of Administration." *Journal of Autoimmunity*, 11: 127-130.

JAVED, N.H., *et al.* (1995) "Exquisite Peptide Specificity of Oral Tolerance in Experimental Autoimmune Encephalomyelities." *The Journal of Immunology*, 155: 1599-1605.

KRUISBEEK, A.M., *et al.* (1992) "Mechanism of Tolerance Induction." *Mechanisms of Lymphocyte Activation and Immune Regulation IV: Cellular Communications* edited by S. Gupta and T.A. Waldmann, Plenum Press, New York, pgs. 101-109.

LOWRY, O.H., *et al.* (1951) "Protein Measurement with the Folin Phenol Reagent." *J. Biol. Chem.* 193: 265-275.

MUDERSPACH, L, *et al.* (2000) "A Phase I Trial of a Human Papillomavirus (HPV) Peptide Vaccine for Women with High-Grade Cervical and Vulvar Intraepithelial Neoplasia who are HPV 16 Positive." *Clinical Cancer Research*, 6: 3406-3416.